Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback